NASDAQ
Hemab Therapeutics Holdings, Inc. (COAG)
♥ 761 Thanks from members
Hemab Therapeutics (COAG) presents a polarized high-risk, high-upside orphan biotech profile, bolstered by a robust $457.5M cash runway following its May 2026 IPO, FDA-endorsed Phase 3 readiness for sutacimig in Glanzmann thrombasthenia, and strong ISTH 2026 data, yet weighed down by zero revenue, widened net losses, and bearish technical patterns.